title: Comparison of the anti-tumor effects of two platinum agents (miriplatin and fine-powder cisplatin).
abstract: OBJECTIVE
  This study was designed to evaluate the anti-tumor effects of miriplatin-lipidol and fine-powder cisplatin-lipiodol suspensions.
  
  
  METHODS
  Assessment of the cytotoxicity of two drugs was performed: a soluble derivative of miriplatin (DPC) and fine-powder cisplatin. We randomly divided 15 rabbits with transplanted VX2 liver tumors into three equal groups. They were infused via the proper hepatic artery with a miriplatin-lipiodol suspension (ML), a fine-powder cisplatin-lipiodol suspension (CL), or saline (control) and the tumor growth rate was determined on MR images acquired before and 7 days after treatment. The concentration of platinum (PCs) in blood was assayed immediately, and 10, 30, and 60 min, and 24 h and 7 days after drug administration. Its concentration in tumor and surrounding normal liver tissues was determined at 7 days postadministration.
  
  
  RESULTS
  At high concentrations, fine-powder cisplatin exhibited stronger cytotoxicity than DPC. At low concentrations, both agents manifested weak cytotoxicity. While there was no difference between the tumor growth rate of the ML and the CL groups, the difference between the controls and ML- and CL-treated rabbits was significant. The blood PCs peaked at 10 min and then gradually decreased over time. On the other hand, no platinum was detected at any point after the administration of ML. There was no difference between the ML and CL groups in the PCs in tumor tissues; however, in normal hepatic tissue, the PCs were higher in ML- than CL-treated rabbits.
  
  
  CONCLUSIONS
  We confirmed the anti-tumor effect of ML and CL. There was no significant difference between the anti-tumor effect of ML and CL at 7 days postadministration.
authors.affiliation: Department of Radiology, Shiga University of Medical Science, Tsukinowa-cho, Seta, Otsu, Shiga 520-2192, Japan. swat@belle.shiga-med.ac.jp
authors.forename: Shobu
authors.initials: S
authors.lastname: Watanabe
authors.forename: Norihisa
authors.initials: N
authors.lastname: Nitta
authors.forename: Shinichi
authors.initials: S
authors.lastname: Ohta
authors.forename: Akinaga
authors.initials: A
authors.lastname: Sonoda
authors.forename: Hideji
authors.initials: H
authors.lastname: Otani
authors.forename: Yuki
authors.initials: Y
authors.lastname: Tomozawa
authors.forename: Ayumi
authors.initials: A
authors.lastname: Nitta-Seko
authors.forename: Keiko
authors.initials: K
authors.lastname: Tsuchiya
authors.forename: Toyohiko
authors.initials: T
authors.lastname: Tanka
authors.forename: Masashi
authors.initials: M
authors.lastname: Takahashi
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Murata
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D006528:Carcinoma, Hepatocellular / Q000097:blood / Q000737:chemistry / Q000188:drug therapy* / Q000473:pathology; D002626:Chemistry, Pharmaceutical; D002945:Cisplatin / Q000008:administration & dosage* / Q000493:pharmacokinetics; D004998:Ethiodized Oil / Q000008:administration & dosage; D006367:HeLa Cells; D006801:Humans; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000097:blood / Q000737:chemistry / Q000188:drug therapy* / Q000473:pathology; D009944:Organoplatinum Compounds / Q000008:administration & dosage* / Q000493:pharmacokinetics; D011208:Powders; D011817:Rabbits; D011897:Random Allocation; D013535:Suspensions; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D011208:Powders; D013535:Suspensions; C406530:miriplatin; D004998:Ethiodized Oil; D002945:Cisplatin